Helsinn Group is a privately-owned Swiss pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. The company is committed to improving the lives of patients by building upon its strong foundation in cancer supportive care and expanding into new therapeutic areas, including rare diseases. Helsinn guides an idea from research and development through to manufacturing, commercialization, and medical affairs, with a global presence spanning approximately 190 countries.
The Lugano headquarters serves as the central hub for global operations, strategic decision-making, research and development oversight, and corporate functions.
The headquarters likely features modern office spaces and facilities designed to support a global pharmaceutical business, fostering collaboration and innovation.
The work culture at Helsinn's HQ is expected to be driven by scientific excellence, ethical practices, patient-centricity, and a collaborative environment, reflecting Swiss precision and a commitment to quality.
The Lugano headquarters is significant as it anchors Helsinn's worldwide operations, from where it coordinates its efforts in research, development, manufacturing, and commercialization of treatments for cancer and rare diseases.
Helsinn Group supports patients in approximately 190 countries worldwide through its own operations and a network of local licensing partners. Key global functions include research and development, clinical trials management, drug manufacturing and supply, quality assurance, regulatory affairs, and commercialization. This extensive network ensures that Helsinn's innovative treatments for cancer and rare diseases reach patients globally.
Via Piana 26
Lugano
Ticino
Switzerland
Address: Damastown, Mulhuddart, Dublin 15, Ireland
Serves as a strategic manufacturing and operational hub, particularly for supplying products to European and international markets, leveraging Ireland's strong pharmaceutical industry infrastructure.
Address: 200 Wood Avenue South, Suite 200, Iselin, NJ 08830, USA
Manages all commercial activities for the significant U.S. market, ensuring patients in the United States have access to Helsinn's cancer care and rare disease therapies.
Address: Helsinn Pharmaceutical Technology (Beijing) Co., Ltd., Unit 09A, 20F, Borui Plaza, No. A26 East 3rd Ring North Road, Chaoyang District, Beijing, China
Facilitates market access, partnerships, and commercial activities in China, a key growth market for pharmaceutical products.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Helsinn Group' leadership includes:
Helsinn Group has been backed by several prominent investors over the years, including:
Based on publicly available information, Helsinn Group's core executive team has shown stability. No major high-profile exits or new hires to the top executive roles (CEO, COO, CFO level) have been widely publicized in the last 12 months. Leadership changes, if any, have been internal or not prominently announced.
Discover the tools Helsinn Group uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Helsinn Group likely uses a standardized email format for its employees. Common formats for companies of this nature include [first_initial][last]@[company_domain] or [first].[last]@[company_domain].
flast@helsinn.com (e.g., jdoe@helsinn.com) or first.last@helsinn.com (e.g. jane.doe@helsinn.com)
Format
gcalderari@helsinn.com
Example
75%
Success rate
Helsinn Group Press Release • 2024-02-05
Helsinn Group and Chugai Pharma Taiwan Ltd. announced that the Taiwan Food and Drug Administration (TFDA) has granted marketing authorization for AKYNZEO® oral capsule for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy (HEC) and moderately emetogenic cancer chemotherapy (MEC)....more
Helsinn Group Press Release • 2023-10-10
Helsinn Group announced the appointment of Richard J. Urban as the new General Manager of Helsinn Therapeutics (US) Inc. (HTU), its US sales and marketing affiliate, effective October 9, 2023. This news is slightly outside the 12-month window for executive *team* changes at Group level but relevant for a key subsidiary leadership....more
Helsinn Group Press Release • 2023-06-26
Helsinn Group and its partner Ohara Pharmaceutical Co., Ltd. announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted marketing authorization for AKYNZEO® IV formulation (fosnetupitant 235 mg / palonosetron 0.25 mg) for the prevention of nausea and vomiting associated with cancer chemotherapy....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Helsinn Group, are just a search away.